The Industry’s First and Largest Fully Decentralized Clinical Megatrial

Downloadable Case Study

The Impact of ADAPTABLE: The Industry's First and Largest Fully Decentralized Clinical Megatrial

Enhancing Site and Patient Engagement

For over half a century, millions of Americans living with heart disease have relied on a daily dose of aspirin to help prevent a heart attack or stroke. While commonly prescribed dosages had been 81 or 325 mg, the award-winning ADAPTABLE study was developed to determine the dosage that maximized results while minimizing side effects.

ADAPTABLE was designed to support more representative inclusion of patients, enhance engagement while reducing the burden on patients to participate in a clinical trial, and decrease many of the costs associated with traditional site-based studies.

“The fact that ADAPTABLE was identified as one of the Top Ten influential clinical trials is recognition that its many lessons learned have had an impact on decentralized trial design.”
Dr. Schuyler Jones
ADAPTABLE Co-Principal Investigator, Associate Professor of Medicine, Duke University Medical Center